세계의 2형 당뇨병 시장 규모 조사 및 예측 : 약효군별, 용도별, 지역별 분석(2023-2030년)

Global Type 2 Diabetes Market is valued approximately at USD 32.32 billion in 2022 and is anticipated to grow with a compounded annual growth rate of more than 8.4% over the forecast period 2023-2030. Type 2 Diabetes, also known as adult-onset diabetes or non-insulin-dependent diabetes is a chronic metabolic disorder characterized by high blood sugar levels. It is the most common form of diabetes accounting for approximately 90% to 95% of all diagnosed cases. Unlike type one diabetes, which is an autoimmune condition where the body fails to produce insulin type two diabetes is characterized by insulin resistance and inadequate insulin production. Increasing number of diabetic patients and growing geriatric population elucidate as the growth drivers of this market during the forecast period.

According to the World Health Organization, diabetes may afflict 537 million adults globally in 2021, with one in ten experiencing other diabetes. According to the World Bank Group in 2022, the world old population was 727 million in 2020, and it is predicted to rise over the next three decades, reaching 1.5 billion in 2050. However, lack of awareness of disease and limited treatment options availability may hamper the growth space of this market. Furthermore, emerging pharma sector and increasing prevalence of type 2 diabetes anticipated to elevate the growth of the Global Type 2 Diabetes Market.

The key regions considered for the Global Type 2 Diabetes Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the type 2 diabetes market. The region's market growth is driven by the increasing prevalence of diabetes, with over 29 million individuals affected, expected to rise to 32 million by 2025. Notably, the United States alone had more than 25 million diabetic patients in 2019. The expansion of the healthcare sector, favorable government regulations, and a growing number of initiatives and favorable reimbursement policies contribute to the overall growth of the type 2 diabetes market in North America. Europe is anticipated to exhibit the highest growth rate among regions. Within Europe, the type 2 diabetes market is primarily dominated by the United Kingdom. The increasing number of patients with type 2 diabetes is a key driver for market growth in the region. Factors such as escalating research and development activities and the rising prevalence of obesity contribute to the demand for type 2 diabetes drugs. Furthermore, enhanced supply chain management presents favorable opportunities for the expansion of the type 2 diabetes market in Europe.

Major market players included in this report are:

• Amgen Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co. Ltd
• Eli Lilly and Co.
• Merck & Co. Inc
• Novo Nordisk AS
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd
• Novartis AG

Recent Developments in the Market:

• In October 2022, Glenmark Pharmaceuticals introduced a novel medication called Zita D, intended for the treatment of patients with type 2 diabetes, particularly those who also have a comorbid condition.
• In March 2019, Novo Nordisk announced its plans to invest approximately USD 98 million in the expansion and advancement of its insulin medicine manufacturing facility located in Denmark. The completion of this project is anticipated to occur by the conclusion of 2020.

Global Type 2 Diabetes Market Report Scope:

• Historical Data: 2020 - 2021
• Base Year for Estimation: 2022
• Forecast period: 2023-2030
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Drug Class, Application, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-Like Peptide Receptor Agonists
• Thiazolidinediones
• Alpha-Glucosidase Inhibitors
• Sulfonylureas & Other Insulin Secretagogues
• Biguanides
• Sodium Glucose Cotransport 2 Inhibitors

By Application:

• Glycaemic Control
• Cardiovascular Safety
• Hypoglycaemia Avoidance
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Type 2 Diabetes Market, by region, 2020-2030 (USD Billion)
  • 1.2.2. Type 2 Diabetes Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3. Type 2 Diabetes Market, by Application, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Type 2 Diabetes Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Type 2 Diabetes Market Dynamics

• 3.1. Type 2 Diabetes Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing Number of Diabetes Patients
    • 3.1.1.2. Growing Geriatric Population
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of Awareness of Disease
    • 3.1.2.2. Limited Treatment Options Available
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Emerging Pharma Sector
    • 3.1.3.2. Increasing Prevalence of Type 2 Diabetes

Chapter 4. Global Type 2 Diabetes Market: Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economic
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Type 2 Diabetes Market, by Drug Class

• 5.1. Market Snapshot
• 5.2. Global Type 2 Diabetes Market by Drug Class, Performance - Potential Analysis
• 5.3. Global Type 2 Diabetes Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4. Type 2 Diabetes Market, Sub Segment Analysis
  • 5.4.1. Dipeptidyl Peptidase-4 Inhibitors
  • 5.4.2. Glucagon-Like Peptide
  • 5.4.3. Receptor Agonists
  • 5.4.4. Thiazolidinediones
  • 5.4.5. Alpha-Glucosidase Inhibitors
  • 5.4.6. Sulfonylureas and other Secretagogues
  • 5.4.7. Biguanides
  • 5.4.8. Sodium Glucose Cotransport 2 Inhibitors

Chapter 6. Global Type 2 Diabetes Market, by Application

• 6.1. Market Snapshot
• 6.2. Global Type 2 Diabetes Market by Application, Performance - Potential Analysis
• 6.3. Global Type 2 Diabetes Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 6.4. Type 2 Diabetes Market, Sub Segment Analysis
  • 6.4.1. Glycaemic Control
  • 6.4.2. Cardiovascular Safety
  • 6.4.3. Hypoglycaemia Avoidance
  • 6.4.4. Others

Chapter 7. Global Type 2 Diabetes Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Type 2 Diabetes Market, Regional Market Snapshot
• 7.4. North America Type 2 Diabetes Market
  • 7.4.1. U.S. Type 2 Diabetes Market
    • 7.4.1.1. Drug Class breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. Application breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Type 2 Diabetes Market
• 7.5. Europe Type 2 Diabetes Market Snapshot
  • 7.5.1. U.K. Type 2 Diabetes Market
  • 7.5.2. Germany Type 2 Diabetes Market
  • 7.5.3. France Type 2 Diabetes Market
  • 7.5.4. Spain Type 2 Diabetes Market
  • 7.5.5. Italy Type 2 Diabetes Market
  • 7.5.6. Rest of Europe Type 2 Diabetes Market
• 7.6. Asia-Pacific Type 2 Diabetes Market Snapshot
  • 7.6.1. China Type 2 Diabetes Market
  • 7.6.2. India Type 2 Diabetes Market
  • 7.6.3. Japan Type 2 Diabetes Market
  • 7.6.4. Australia Type 2 Diabetes Market
  • 7.6.5. South Korea Type 2 Diabetes Market
  • 7.6.6. Rest of Asia Pacific Type 2 Diabetes Market
• 7.7. Latin America Type 2 Diabetes Market Snapshot
  • 7.7.1. Brazil Type 2 Diabetes Market
  • 7.7.2. Mexico Type 2 Diabetes Market
• 7.8. Middle East & Africa Type 2 Diabetes Market
  • 7.8.1. Saudi Arabia Type 2 Diabetes Market
  • 7.8.2. South Africa Type 2 Diabetes Market
  • 7.8.3. Rest of Middle East & Africa Type 2 Diabetes Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Amgen Inc.
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. AstraZeneca PLC
  • 8.3.3. Boehringer Ingelheim International GmbH
  • 8.3.4. Daiichi Sankyo Co. Ltd
  • 8.3.5. Eli Lilly and Co.
  • 8.3.6. Merck & Co. Inc
  • 8.3.7. Novo Nordisk AS
  • 8.3.8. Sanofi SA
  • 8.3.9. Takeda Pharmaceutical Co. Ltd
  • 8.3.10. Novartis AG

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption